Travere Therapeutics officer proposes $91.2K share sale

The Rule 10b5-1 plan adoption or instruction date listed for the proposed sale is June 16, 2025.

Accepted by SEC EDGAR 05/06/2026 - 04:03 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Travere Therapeutics, Inc. officer Elizabeth Reed reported a proposed sale of 2,076 common shares, with an aggregate market value of $91,240.20 and an approximate sale date of May 6, 2026. She also reported acquiring 2,076 performance shares from the issuer on May 4, 2026. Common shares outstanding were listed at 92,992,905. The Rule 10b5-1 plan adoption or instruction date is June 16, 2025. Reed’s other reported common-share sales were dated February 17, 2026, through May 5, 2026.

Key Figures

Proposed sale: 2,076 common shares Aggregate market value: $91,240.20 Common shares outstanding: 92,992,905 shares +1 more

4 metrics

Proposed sale 2,076 common shares Approximate sale date: May 6, 2026

Aggregate market value $91,240.20 Proposed sale of common shares

Common shares outstanding 92,992,905 shares Travere Therapeutics, Inc.

Performance shares acquired 2,076 shares Acquired from the issuer on May 4, 2026

Key Terms

Performance Shares, Aggregate Market Value, Rule 10b5-1

3 terms

Performance Shares financial

"Nature of Acquisition Transaction: Performance Shares"

Performance shares are a type of company stock given to executives or employees that only become theirs if the company meets specific goals, like hitting certain profits or growth targets. They motivate leaders to work toward the company’s success, because their additional shares depend on achieving these results.

Aggregate Market Value financial

"Aggregate Market Value"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Rule 10b5-1 regulatory

"Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TVTX shares is Elizabeth Reed proposing to sell?

Elizabeth Reed reported a proposed sale of 2,076 common shares, with an aggregate market value of $91,240.20 and an approximate sale date of May 6, 2026.

Which broker is listed for Elizabeth Reed’s proposed TVTX sale?

Morgan Stanley Smith Barney LLC is listed as the broker for the proposed sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001283303
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TRAVERE THERAPEUTICS, INC.
SEC File Number	001-36257
Address of Issuer	3611 Valley Centre Drive Suite 300 San Diego CALIFORNIA 92130
Phone	888-969-7879
Name of Person for Whose Account the Securities are To Be Sold	ELIZABETH REED
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	2076	91240.20	92992905	05/06/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/04/2026	Performance Shares	ISSUER			2076	05/04/2026	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
ELIZABETH REED 3611 Valley Centre Drive Suite 300 San Diego CA 92130	Common	05/05/2026	2174	101417.10
ELIZABETH REED 3611 Valley Centre Drive Suite 300 San Diego CA 92130	Common	05/04/2026	20000	900000.00
ELIZABETH REED 3611 Valley Centre Drive Suite 300 San Diego CA 92130	Common	04/15/2026	6785	283823.34
ELIZABETH REED 3611 Valley Centre Drive Suite 300 San Diego CA 92130	Common	04/14/2026	37500	1540125.00
ELIZABETH REED 3611 Valley Centre Drive Suite 300 San Diego CA 92130	Common	04/14/2026	7215	302516.29
ELIZABETH REED 3611 Valley Centre Drive Suite 300 San Diego CA 92130	Common	04/01/2026	10000	300000.00
ELIZABETH REED 3611 Valley Centre Drive Suite 300 San Diego CA 92130	Common	03/16/2026	10000	280861.00
ELIZABETH REED 3611 Valley Centre Drive Suite 300 San Diego CA 92130	Common	02/17/2026	10000	278317.00

144: Remarks and Signature

Remarks
Date of Notice	05/06/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/16/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Elizabeth E. Reed
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)